DeepMed Research

Cilostazol

Generic Name: Cilostazol

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₇N_₅O_₂

CAS Number: 73963-72-1

Unique Ingredient Identifier: N7Z035406B

Background: Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions.

Indication: Indicated for the alleviation of symptoms of intermittent claudication (pain in the legs that occurs with walking and disappears with rest).

Associated Conditions: Intermittent Claudication

Clinical Trials

Pharmacokinetic Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers

Phase 1

Completed

Conditions: Intermittent Claudication

Interventions: Drug: PMR 150 mg
Drug: PMR 200 mg
Drug: Cilostazol 100 mg

First Posted Date: 2018-03-29

Last Posted Date: 2018-07-10

Lead Sponsor: Genovate Biotechnology Co., Ltd.,

Target Recruit Count: 21

Registration Number: NCT03480321

Locations: 🇺🇸
Bio-Kinetic Clinical Applications, LLC, Springfield, Missouri, United States

LACunar Intervention (LACI-2) Trial-2

Phase 2

Completed

Conditions: Cerebral Small Vessel Diseases
Stroke, Lacunar

Interventions: Drug: Isosorbide Mononitrate XL (ISMN)
Drug: ISMN XL and Cilostazol
Other: Neither ISMN nor cilostazol
Drug: Cilostazol

First Posted Date: 2018-03-02

Last Posted Date: 2024-11-11

Lead Sponsor: University of Edinburgh

Target Recruit Count: 363

Registration Number: NCT03451591

Locations: 🇬🇧
Royal Infirmary, Edinburgh, Lothian, United Kingdom

The Effect of Sumatriptan and Placebo Injection on Cilostazol Induced Headache

Not Applicable

Completed

Conditions: Migraine

Interventions: Drug: Cilostazol 200mg
Drug: SUMAtriptan 6 MG/ML
Drug: Placebo

First Posted Date: 2018-02-06

Last Posted Date: 2020-01-29

Lead Sponsor: Danish Headache Center

Target Recruit Count: 30

Registration Number: NCT03422796

Locations: 🇩🇰
Rigshospitalet Glostrup, Glostrup, Denmark

Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes

Phase 4

Completed

Conditions: Carotid Atherosclerosis
Type 2 Diabetes Mellitus

Interventions: Drug: Aspirin
Drug: Cilostazol

First Posted Date: 2017-08-14

Last Posted Date: 2020-04-08

Lead Sponsor: Seoul National University Bundang Hospital

Target Recruit Count: 50

Registration Number: NCT03248401

Locations: 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of

The Effect of Cilostazol Compared to Aspirin on Endothelial Function in Acute Cerebral Ischemia Patients

Phase 4

Completed

Conditions: Ischemic Stroke
Endothelial Dysfunction

Interventions: Drug: Cilostazol 100mg
Drug: Aspirin

First Posted Date: 2017-04-17

Last Posted Date: 2017-04-17

Lead Sponsor: Ajou University School of Medicine

Target Recruit Count: 80

Registration Number: NCT03116269

Locations: 🇰🇷
Ajou University Medical Center, Suwon, Gyunggido, Korea, Republic of

Diabetic Artery Obstruction: is it Possible to Reduce Ischemic Events With Cilostazol?

Phase 4

Completed

Conditions: Ischemic Stroke
Peripheral Artery Disease
Diabetes Mellitus, Type 2

Interventions: Drug: Clopidogrel
Drug: Cilostazol

First Posted Date: 2016-12-06

Last Posted Date: 2020-12-29

Lead Sponsor: University of Ioannina

Target Recruit Count: 826

Registration Number: NCT02983214

Locations: 🇬🇷
Atherothrombosis Research Centre / Laboratory of Biochemistry, University of Ioannina, Ioannina, Epirus, Greece

Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients

Phase 4

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Cilostazol
Drug: Acetylsalicylic acid

First Posted Date: 2016-10-14

Last Posted Date: 2016-10-14

Lead Sponsor: Kangbuk Samsung Hospital

Target Recruit Count: 116

Registration Number: NCT02933788

Comparison of Cilostazol-based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy for Outcomes of below-the Knee Endovascular Intervention in Patients With Critical Limb Ischemia (TAP CLI Study)

Phase 4

Conditions: Critical Limb Ischemia

Interventions: Drug: Triple antiplatelet therapy (aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) )
Drug: Dual antiplatelet therapy (aspirin (100 mg) and clopidogrel (75 mg)) using aspirin and clopidogrel
Drug: Dual antiplatelet therapy (aspirin (100 mg) and cilostazol (200 mg)) using aspirin and cilostazol

First Posted Date: 2016-07-12

Last Posted Date: 2019-01-14

Lead Sponsor: Yonsei University

Target Recruit Count: 390

Registration Number: NCT02829151

Locations: 🇰🇷
Division of Cardiology, Department of Internal Medicine, Severance Hospital, Seoul, Korea, Republic of

Cilostazol Following Peripheral Endovascular Procedures

Phase 3

Conditions: Peripheral Arterial Disease

Interventions: Drug: Cilostazol
Drug: Aspirin

First Posted Date: 2016-05-12

Last Posted Date: 2021-01-12

Lead Sponsor: Attikon Hospital

Target Recruit Count: 200

Registration Number: NCT02770274

Locations: 🇬🇷
Patras Universityu Hospital, Patras, Achaia, Greece
🇬🇷
Attikon university General Hospital, Athens, Attiki, Greece

Pharmacodynamic Study of Cilostazol in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Cilostazol
Drug: Acetylsalicylic acid
Drug: Clopidogrel

First Posted Date: 2015-09-18

Last Posted Date: 2021-10-13

Lead Sponsor: Otsuka Pharmaceutical Co., Ltd.

Target Recruit Count: 77

Registration Number: NCT02554721

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy